Sponsors (4)
The resolution could improve prevention and outcomes for DVT/PE and lower related healthcare costs by raising awareness, but it is largely symbolic unless paired with funding or concrete programs and could reallocate scarce public health resources.
Hospitals and patients (especially those hospitalized) may see fewer preventable deep vein thrombosis (DVT) and pulmonary embolism (PE) cases because the designation raises awareness and encourages prevention measures.
Taxpayers and the healthcare system could see lower medical spending if increased prevention reduces DVT/PE incidence — potentially lowering up to roughly $10 billion in incremental annual costs.
Cancer patients may benefit from earlier monitoring and treatment for cancer-associated clots due to heightened awareness, which can improve outcomes and survival odds.
The designation is non‑binding and provides no new funding or mandates, so it may create expectations without producing concrete prevention programs or resources.
Without dedicated funding, awareness activities could divert limited public health resources or attention from other priorities at the state and local level.
Based on analysis of 1 section of legislative text.
Designates March as a national Deep Vein Thrombosis and Pulmonary Embolism Awareness Month and records findings on incidence, risks, deaths, and costs.
Official title: Supporting the goals and ideals of "Deep Vein Thrombosis and Pulmonary Embolism Awareness Month".
Introduced April 14, 2026 by Charles Ernest Grassley · Last progress April 14, 2026
Designates March as a national Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Awareness Month and states findings about the scope, risk factors, outcomes, and costs of these conditions. The resolution summarizes that DVT and PE affect up to 900,000 people annually in the United States, cause tens of thousands of deaths each year, are often preventable, and disproportionately affect people with cancer, pregnant and postpartum people, older adults, and those with immobility or recent surgery. The purpose is educational and awareness-raising rather than regulatory or funding-related: it encourages spotlighting prevention, risk recognition, and early treatment to reduce morbidity, mortality, and healthcare costs associated with DVT and PE.